Veracyte Q1 revenue rises 18% to $114.5 million; net income $7.0 million
Veracyte reported first-quarter 2025 total revenue of $114.5 million, up 18% from a year earlier, and net income of $7.0 million, compared with a net loss of $1.9 million in the same quarter of 2024. The company reiterated its 2025 testing revenue guidance of $470 million to $480 million and raised its adjusted EBITDA margin outlook to 22.5% from 21.6%, but it also said its French subsidiary Veracyte SAS has entered collective proceedings in a Marseille commercial court and that the parent will no longer fund that entity.
Key points
- Total revenue $114.5 million, up 18%; testing revenue $107.3 million, up 19%
- Net income $7.0 million, or $0.09 diluted per share, versus a net loss of $1.9 million a year earlier
- 2025 adjusted EBITDA margin guidance raised to 22.5% from 21.6%; testing revenue guidance reiterated at $470 million to $480 million
- Veracyte SAS court process expected to finish by end of 2025; the company recorded $3.8 million of related expense in the quarter
The filing
Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.